Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
About
  2. products
  3. rna therapeutics

RNA Therapeutics

SHARE
The OligoPhore™ / SemaPhore™ technology has been extensively and successfully tested with various siRNA and mRNA sequences in numerous disease models in mice. For the development of our first proprietary drug product, AM-401 (OligoPhore™ siRNA targeting KRAS), we have initiated a program of IND-enabling studies.
Most popular related searches
pancreas cancer
cancer cell
in vivo model
drug production
disease modeling
tumor microenvironment
pancreas
cancer evaluation
in vitro cell
preclinical trial

The effects of OligoPhore™ delivered siRNA in KRAS driven cancer were evaluated in vitro and in vivo in colorectal and pancreatic cancer assays and animal models (Strand et al., 2019). The KRAS gene acts as an on/off switch for cell growth. However, when the gene is mutated, KRAS may allow cells to grow uncontrollably and activate the downstream pathways. This leads to multiplication of cells and cancer growth, which in turn can cause metastases.

The study demonstrated that the nanoparticles were avidly taken up by cancer cells in vitro, could deliver KRAS-specific siRNA, inhibited KRAS expression, and reduced cell viability. Further, the study showed that OligoPhore™ can deliver siRNA to the tumor microenvironment, reduce KRAS expression, and inhibit pancreatic cancer growth in vivo. In a spontaneous model of pancreatic cancer, OligoPhore™ demonstrated its ability to effectively deliver siRNA to tumors which are difficult to reach.

The OligoPhore™ and SemaPhore™ platforms are currently in the preclinical stage.